The cost, risk, and time it takes to bring a new product to market has led some life sciences companies to get creative about how they fund their R&D efforts. Profitability has been constrained by pricing challenges, rising material costs, and more stringent regulations, among other pressures.

Recent research [1] from Deloitte found that R&D returns have declined to 1.9 percent, down from 10.1 percent in 2010 — the lowest level in nine years. Returns have been similarly affected by the growing…

Boston Biz Journal https://www.bizjournals.com/boston/news/2019/06/01/life-sciences-companies-should-tread-cautiously.html?ana=RSS&s=article_search